Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Jämförelse av standardbehandling med en triplettkombination av målinriktade immunterapeutiska medel

21 oktober 2026 uppdaterad av: National Cancer Institute (NCI)

En randomiserad fas II-studie av triplettterapi (en PD-L1-hämmare Durvalumab (MEDI4736) i kombination med Olaparib och Cediranib) jämfört med Olaparib och Cediranib eller Durvalumab (MEDI4736) och Cediranib eller Standard of Care Requireant Platinum-Resurrent kemoterapi vid kvinnor med epitheli Ovariecancer, primär peritonealcancer eller äggledarcancer som tidigare har fått Bevacizumab

This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type of treatment most patients with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of durvalumab, olaparib and cediranib may work better in increasing the duration of time that the cancer does not progress compared to the usual treatment.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Intervention / Behandling

Detaljerad beskrivning

PRIMARY OBJECTIVE:

I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by progression-free survival (PFS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.

SECONDARY OBJECTIVES:

I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.

II. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by overall survival (OS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.

OUTLINE: Patients are randomized to 1 of 4 arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on study. Patients also undergo collection of blood and computed tomography (CT) with contrast during screening, and CT or magnetic resonance imaging (MRI) scans throughout the trial.

ARM II: Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate orally (PO) once daily (QD) Monday through Friday, and olaparib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.

ARM III: Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.

ARM IV: Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.

After completion of study treatment, patients are followed up periodically for up to 5 years.

Studietyp

Interventionell

Inskrivning (Faktisk)

120

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Förenta staterna
    • Alaska
      • Anchorage, Alaska, Förenta staterna, 98508
        • Anchorage Associates in Radiation Medicine
      • Anchorage, Alaska, Förenta staterna, 99508
        • Alaska Breast Care and Surgery LLC
      • Anchorage, Alaska, Förenta staterna, 99508
        • Alaska Oncology and Hematology LLC
      • Anchorage, Alaska, Förenta staterna, 99508
        • Alaska Women's Cancer Care
      • Anchorage, Alaska, Förenta staterna, 99508
        • Anchorage Oncology Centre
      • Anchorage, Alaska, Förenta staterna, 99508
        • Katmai Oncology Group
      • Anchorage, Alaska, Förenta staterna, 99508
        • Providence Alaska Medical Center
      • Anchorage, Alaska, Förenta staterna, 99504
        • Anchorage Radiation Therapy Center
      • Fairbanks, Alaska, Förenta staterna, 99701
        • Fairbanks Memorial Hospital
    • Arizona
      • Goodyear, Arizona, Förenta staterna, 85338
        • CTCA at Western Regional Medical Center
      • Phoenix, Arizona, Förenta staterna, 85004
        • Cancer Center at Saint Joseph's
    • Arkansas
      • Fort Smith, Arkansas, Förenta staterna, 72903
        • Mercy Hospital Fort Smith
      • Hot Springs, Arkansas, Förenta staterna, 71913
        • CHI Saint Vincent Cancer Center Hot Springs
      • Little Rock, Arkansas, Förenta staterna, 72205
        • University of Arkansas for Medical Sciences
    • California
      • Arroyo Grande, California, Förenta staterna, 93420
        • Mission Hope Medical Oncology - Arroyo Grande
      • Auburn, California, Förenta staterna, 95602
        • Sutter Auburn Faith Hospital
      • Auburn, California, Förenta staterna, 95603
        • Sutter Cancer Centers Radiation Oncology Services-Auburn
      • Berkeley, California, Förenta staterna, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Burbank, California, Förenta staterna, 91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • Cameron Park, California, Förenta staterna, 95682
        • Sutter Cancer Centers Radiation Oncology Services-Cameron Park
      • Castro Valley, California, Förenta staterna, 94546
        • Eden Hospital Medical Center
      • Concord, California, Förenta staterna, 94520
        • John Muir Medical Center-Concord
      • Davis, California, Förenta staterna, 95616
        • Sutter Davis Hospital
      • Duarte, California, Förenta staterna, 91010
        • City of Hope Comprehensive Cancer Center
      • Fremont, California, Förenta staterna, 94538
        • Palo Alto Medical Foundation-Fremont
      • Lancaster, California, Förenta staterna, 93534
        • City of Hope Antelope Valley
      • Los Angeles, California, Förenta staterna, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, Förenta staterna, 90033
        • Los Angeles General Medical Center
      • Modesto, California, Förenta staterna, 95355
        • Memorial Medical Center
      • Mountain View, California, Förenta staterna, 94040
        • Palo Alto Medical Foundation-Camino Division
      • Mountain View, California, Förenta staterna, 94040
        • Palo Alto Medical Foundation-Gynecologic Oncology
      • Palo Alto, California, Förenta staterna, 94301
        • Palo Alto Medical Foundation Health Care
      • Roseville, California, Förenta staterna, 95661
        • Sutter Cancer Centers Radiation Oncology Services-Roseville
      • Roseville, California, Förenta staterna, 95661
        • Sutter Roseville Medical Center
      • Sacramento, California, Förenta staterna, 95816
        • Sutter Medical Center Sacramento
      • San Francisco, California, Förenta staterna, 94115
        • California Pacific Medical Center-Pacific Campus
      • San Luis Obispo, California, Förenta staterna, 93401
        • Pacific Central Coast Health Center-San Luis Obispo
      • Santa Cruz, California, Förenta staterna, 95065
        • Palo Alto Medical Foundation-Santa Cruz
      • Santa Maria, California, Förenta staterna, 93444
        • Mission Hope Medical Oncology - Santa Maria
      • Santa Rosa, California, Förenta staterna, 95403
        • Sutter Pacific Medical Foundation
      • South Pasadena, California, Förenta staterna, 91030
        • City of Hope South Pasadena
      • Sunnyvale, California, Förenta staterna, 94086
        • Palo Alto Medical Foundation-Sunnyvale
      • Upland, California, Förenta staterna, 91786
        • City of Hope Upland
      • Vallejo, California, Förenta staterna, 94589
        • Sutter Solano Medical Center/Cancer Center
      • Walnut Creek, California, Förenta staterna, 94598
        • John Muir Medical Center-Walnut Creek
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80012
        • Rocky Mountain Cancer Centers-Aurora
      • Boulder, Colorado, Förenta staterna, 80304
        • Rocky Mountain Cancer Centers-Boulder
      • Centennial, Colorado, Förenta staterna, 80112
        • Rocky Mountain Cancer Centers - Centennial
      • Colorado Springs, Colorado, Förenta staterna, 80907
        • Penrose-Saint Francis Healthcare
      • Colorado Springs, Colorado, Förenta staterna, 80907
        • Rocky Mountain Cancer Centers-Penrose
      • Denver, Colorado, Förenta staterna, 80210
        • AdventHealth Porter
      • Durango, Colorado, Förenta staterna, 81301
        • Mercy Medical Center
      • Durango, Colorado, Förenta staterna, 81301
        • CommonSpirit Cancer Center Mercy
      • Lakewood, Colorado, Förenta staterna, 80228
        • CommonSpirit Saint Anthony Hospital Cancer Center
      • Littleton, Colorado, Förenta staterna, 80120
        • Rocky Mountain Cancer Centers-Littleton
      • Littleton, Colorado, Förenta staterna, 80122
        • AdventHealth Littleton
      • Lone Tree, Colorado, Förenta staterna, 80124
        • Rocky Mountain Cancer Centers-Sky Ridge
      • Longmont, Colorado, Förenta staterna, 80501
        • Longmont United Hospital
      • Longmont, Colorado, Förenta staterna, 80501
        • Rocky Mountain Cancer Centers-Longmont
      • Loveland, Colorado, Förenta staterna, 80539
        • Banner North Colorado Medical Center - Loveland Campus
      • Parker, Colorado, Förenta staterna, 80138
        • AdventHealth Parker
      • Pueblo, Colorado, Förenta staterna, 81004
        • Saint Mary Corwin Medical Center
    • Connecticut
      • Danbury, Connecticut, Förenta staterna, 06810
        • Danbury Hospital
      • Norwalk, Connecticut, Förenta staterna, 06856
        • Norwalk Hospital
    • Florida
      • Pensacola, Florida, Förenta staterna, 32504
        • Sacred Heart Hospital
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30342
        • Northside Hospital
      • Newnan, Georgia, Förenta staterna, 30265
        • CTCA at Southeastern Regional Medical Center
    • Hawaii
      • Honolulu, Hawaii, Förenta staterna, 96813
        • Queen's Medical Center
      • Honolulu, Hawaii, Förenta staterna, 96826
        • Kapiolani Medical Center for Women and Children
    • Idaho
      • Boise, Idaho, Förenta staterna, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Boise, Idaho, Förenta staterna, 83712
        • Saint Luke's Cancer Institute - Boise
      • Caldwell, Idaho, Förenta staterna, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Förenta staterna, 83814
        • Kootenai Health - Coeur d'Alene
      • Emmett, Idaho, Förenta staterna, 83617
        • Walter Knox Memorial Hospital
      • Fruitland, Idaho, Förenta staterna, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Förenta staterna, 83642
        • Idaho Urologic Institute-Meridian
      • Meridian, Idaho, Förenta staterna, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Förenta staterna, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Förenta staterna, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Förenta staterna, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Förenta staterna, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
      • Twin Falls, Idaho, Förenta staterna, 83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Alton, Illinois, Förenta staterna, 62002
        • OSF Saint Anthony's Health Center
      • Aurora, Illinois, Förenta staterna, 60504
        • Rush-Copley Medical Center
      • Bloomington, Illinois, Förenta staterna, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, Förenta staterna, 61520
        • Illinois CancerCare-Canton
      • Carbondale, Illinois, Förenta staterna, 62902
        • Memorial Hospital of Carbondale
      • Carterville, Illinois, Förenta staterna, 62918
        • SIH Cancer Institute
      • Carthage, Illinois, Förenta staterna, 62321
        • Illinois CancerCare-Carthage
      • Centralia, Illinois, Förenta staterna, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, Förenta staterna, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, Förenta staterna, 60612
        • John H Stroger Jr Hospital of Cook County
      • Chicago, Illinois, Förenta staterna, 60612
        • Rush MD Anderson Cancer Center
      • Danville, Illinois, Förenta staterna, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, Förenta staterna, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Förenta staterna, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Dixon, Illinois, Förenta staterna, 61021
        • Illinois CancerCare-Dixon
      • Effingham, Illinois, Förenta staterna, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, Förenta staterna, 62401
        • Carle Physician Group-Effingham
      • Eureka, Illinois, Förenta staterna, 61530
        • Illinois CancerCare-Eureka
      • Evanston, Illinois, Förenta staterna, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Galesburg, Illinois, Förenta staterna, 61401
        • Western Illinois Cancer Treatment Center
      • Galesburg, Illinois, Förenta staterna, 61401
        • Illinois CancerCare-Galesburg
      • Geneva, Illinois, Förenta staterna, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, Förenta staterna, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Harvey, Illinois, Förenta staterna, 60426
        • Ingalls Memorial Hospital
      • Highland Park, Illinois, Förenta staterna, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Hinsdale, Illinois, Förenta staterna, 60521
        • Sudarshan K Sharma MD Limited-Gynecologic Oncology
      • Kewanee, Illinois, Förenta staterna, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, Förenta staterna, 61455
        • Illinois CancerCare-Macomb
      • Mattoon, Illinois, Förenta staterna, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Mount Vernon, Illinois, Förenta staterna, 62864
        • SSM Health Good Samaritan
      • New Lenox, Illinois, Förenta staterna, 60451
        • UC Comprehensive Cancer Center at Silver Cross
      • O'Fallon, Illinois, Förenta staterna, 62269
        • Cancer Care Center of O'Fallon
      • Orland Park, Illinois, Förenta staterna, 60462
        • University of Chicago Medicine-Orland Park
      • Ottawa, Illinois, Förenta staterna, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, Förenta staterna, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Förenta staterna, 61636
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, Förenta staterna, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, Förenta staterna, 61354
        • Illinois CancerCare-Peru
      • Peru, Illinois, Förenta staterna, 61354
        • Valley Radiation Oncology
      • Princeton, Illinois, Förenta staterna, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, Förenta staterna, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Förenta staterna, 62702
        • Springfield Clinic
      • Springfield, Illinois, Förenta staterna, 62781
        • Springfield Memorial Hospital
      • Urbana, Illinois, Förenta staterna, 61801
        • Carle Cancer Center
      • Urbana, Illinois, Förenta staterna, 61801
        • The Carle Foundation Hospital
      • Warrenville, Illinois, Förenta staterna, 60555
        • Northwestern Medicine Cancer Center Warrenville
      • Washington, Illinois, Förenta staterna, 61571
        • Illinois CancerCare - Washington
      • Yorkville, Illinois, Förenta staterna, 60560
        • Rush-Copley Healthcare Center
      • Zion, Illinois, Förenta staterna, 60099
        • Midwestern Regional Medical Center
    • Indiana
      • South Bend, Indiana, Förenta staterna, 46601
        • Memorial Hospital of South Bend
    • Iowa
      • Ames, Iowa, Förenta staterna, 50010
        • Mary Greeley Medical Center
      • Ames, Iowa, Förenta staterna, 50010
        • McFarland Clinic - Ames
      • Boone, Iowa, Förenta staterna, 50036
        • McFarland Clinic - Boone
      • Cedar Rapids, Iowa, Förenta staterna, 52403
        • Mercy Hospital
      • Cedar Rapids, Iowa, Förenta staterna, 52403
        • Oncology Associates at Mercy Medical Center
      • Clive, Iowa, Förenta staterna, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, Förenta staterna, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Council Bluffs, Iowa, Förenta staterna, 51503
        • Alegent Health Mercy Hospital
      • Creston, Iowa, Förenta staterna, 50801
        • Greater Regional Medical Center
      • Des Moines, Iowa, Förenta staterna, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Förenta staterna, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Fort Dodge, Iowa, Förenta staterna, 50501
        • McFarland Clinic - Trinity Cancer Center
      • Iowa City, Iowa, Förenta staterna, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • Jefferson, Iowa, Förenta staterna, 50129
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Förenta staterna, 50158
        • McFarland Clinic - Marshalltown
      • West Des Moines, Iowa, Förenta staterna, 50266
        • Mercy Medical Center-West Lakes
    • Kansas
      • Garden City, Kansas, Förenta staterna, 67846
        • Central Care Cancer Center - Garden City
      • Great Bend, Kansas, Förenta staterna, 67530
        • Central Care Cancer Center - Great Bend
    • Kentucky
      • Bardstown, Kentucky, Förenta staterna, 40004
        • CommonSpirit Saint Joseph Hospital - Bardstown
      • Corbin, Kentucky, Förenta staterna, 40701
        • Commonwealth Cancer Center-Corbin
      • Lexington, Kentucky, Förenta staterna, 40504
        • Saint Joseph Radiation Oncology Resource Center
      • Lexington, Kentucky, Förenta staterna, 40509
        • CommonSpirit Saint Joseph Medical Center - East Lexington
      • London, Kentucky, Förenta staterna, 40741
        • CommonSpirit Saint Joseph Hospital London
      • Louisville, Kentucky, Förenta staterna, 40202
        • Jewish Hospital
      • Louisville, Kentucky, Förenta staterna, 40245
        • UofL Health Medical Center Northeast
      • Louisville, Kentucky, Förenta staterna, 40215
        • Saints Mary and Elizabeth Hospital
      • Shepherdsville, Kentucky, Förenta staterna, 40165
        • Jewish Hospital Medical Center South
    • Louisiana
      • Baton Rouge, Louisiana, Förenta staterna, 70817
        • Our Lady of the Lake Medical Oncology
    • Maine
      • Augusta, Maine, Förenta staterna, 04330
        • Harold Alfond Center for Cancer Care
      • Brewer, Maine, Förenta staterna, 04412
        • Lafayette Family Cancer Center-EMMC
      • Scarborough, Maine, Förenta staterna, 04074
        • MaineHealth Maine Medical Center- Scarborough
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21204
        • Greater Baltimore Medical Center
      • Bethesda, Maryland, Förenta staterna, 20892
        • National Institutes of Health Clinical Center
    • Michigan
      • Ann Arbor, Michigan, Förenta staterna, 48109
        • University of Michigan Rogel Cancer Center
      • Dearborn, Michigan, Förenta staterna, 48124
        • Corewell Health Dearborn Hospital
      • Royal Oak, Michigan, Förenta staterna, 48073
        • Corewell Health William Beaumont University Hospital
      • Troy, Michigan, Förenta staterna, 48085
        • Corewell Health Beaumont Troy Hospital
    • Minnesota
      • Burnsville, Minnesota, Förenta staterna, 55337
        • Fairview Ridges Hospital
      • Burnsville, Minnesota, Förenta staterna, 55337
        • Minnesota Oncology - Burnsville
      • Cambridge, Minnesota, Förenta staterna, 55008
        • Cambridge Medical Center
      • Coon Rapids, Minnesota, Förenta staterna, 55433
        • Mercy Hospital
      • Edina, Minnesota, Förenta staterna, 55435
        • Fairview Southdale Hospital
      • Fridley, Minnesota, Förenta staterna, 55432
        • Unity Hospital
      • Maple Grove, Minnesota, Förenta staterna, 55369
        • Fairview Clinics and Surgery Center Maple Grove
      • Maplewood, Minnesota, Förenta staterna, 55109
        • Saint John's Hospital - Healtheast
      • Maplewood, Minnesota, Förenta staterna, 55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Minneapolis, Minnesota, Förenta staterna, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, Förenta staterna, 55407
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, Förenta staterna, 55454
        • Health Partners Inc
      • Minneapolis, Minnesota, Förenta staterna, 55455
        • University of Minnesota/Masonic Cancer Center
      • Monticello, Minnesota, Förenta staterna, 55362
        • Monticello Cancer Center
      • New Ulm, Minnesota, Förenta staterna, 56073
        • New Ulm Medical Center
      • Princeton, Minnesota, Förenta staterna, 55371
        • Fairview Northland Medical Center
      • Robbinsdale, Minnesota, Förenta staterna, 55422
        • North Memorial Medical Health Center
      • Saint Louis Park, Minnesota, Förenta staterna, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, Förenta staterna, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Förenta staterna, 55102
        • United Hospital
      • Shakopee, Minnesota, Förenta staterna, 55379
        • Saint Francis Regional Medical Center
      • Stillwater, Minnesota, Förenta staterna, 55082
        • Lakeview Hospital
      • Waconia, Minnesota, Förenta staterna, 55387
        • Ridgeview Medical Center
      • Willmar, Minnesota, Förenta staterna, 56201
        • Rice Memorial Hospital
      • Woodbury, Minnesota, Förenta staterna, 55125
        • Minnesota Oncology Hematology PA-Woodbury
      • Wyoming, Minnesota, Förenta staterna, 55092
        • Fairview Lakes Medical Center
    • Missouri
      • Ballwin, Missouri, Förenta staterna, 63011
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Bolivar, Missouri, Förenta staterna, 65613
        • Central Care Cancer Center - Bolivar
      • Cape Girardeau, Missouri, Förenta staterna, 63703
        • Saint Francis Medical Center
      • Cape Girardeau, Missouri, Förenta staterna, 63703
        • Mercy Cancer Center - Cape Girardeau
      • Farmington, Missouri, Förenta staterna, 63640
        • Parkland Health Center - Farmington
      • Jefferson City, Missouri, Förenta staterna, 65109
        • MU Health Care Goldschmidt Cancer Center
      • Joplin, Missouri, Förenta staterna, 64804
        • Freeman Health System
      • Joplin, Missouri, Förenta staterna, 64804
        • Mercy Hospital Joplin
      • Rolla, Missouri, Förenta staterna, 65401
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Rolla, Missouri, Förenta staterna, 65401
        • Phelps Health Delbert Day Cancer Institute
      • Saint Joseph, Missouri, Förenta staterna, 64506
        • Heartland Regional Medical Center
      • Sainte Genevieve, Missouri, Förenta staterna, 63670
        • Sainte Genevieve County Memorial Hospital
      • Springfield, Missouri, Förenta staterna, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, Förenta staterna, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, Förenta staterna, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Förenta staterna, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, Förenta staterna, 63109
        • Mercy Infusion Center - Chippewa
      • St Louis, Missouri, Förenta staterna, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, Förenta staterna, 63128
        • Mercy Hospital South
      • Sullivan, Missouri, Förenta staterna, 63080
        • Missouri Baptist Sullivan Hospital
      • Washington, Missouri, Förenta staterna, 63090
        • Mercy Hospital Washington
    • Montana
      • Anaconda, Montana, Förenta staterna, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Förenta staterna, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, Förenta staterna, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, Förenta staterna, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Förenta staterna, 59405
        • Benefis Sletten Cancer Institute
      • Kalispell, Montana, Förenta staterna, 59901
        • Logan Health Medical Center
      • Missoula, Montana, Förenta staterna, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, Förenta staterna, 59804
        • Community Medical Center
    • Nebraska
      • Grand Island, Nebraska, Förenta staterna, 68803
        • Nebraska Cancer Specialists/Oncology Hematology West PC
      • Kearney, Nebraska, Förenta staterna, 68847
        • CHI Health Good Samaritan
      • Lincoln, Nebraska, Förenta staterna, 68510
        • Saint Elizabeth Regional Medical Center
      • Lincoln, Nebraska, Förenta staterna, 68516
        • Cancer Partners of Nebraska
      • Omaha, Nebraska, Förenta staterna, 68114
        • Nebraska Methodist Hospital
      • Omaha, Nebraska, Förenta staterna, 68198
        • University of Nebraska Medical Center
      • Omaha, Nebraska, Förenta staterna, 68124
        • Alegent Health Bergan Mercy Medical Center
      • Omaha, Nebraska, Förenta staterna, 68122
        • Alegent Health Immanuel Medical Center
      • Omaha, Nebraska, Förenta staterna, 68130
        • Alegent Health Lakeside Hospital
      • Papillion, Nebraska, Förenta staterna, 68046
        • Midlands Community Hospital
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89106
        • Women's Cancer Center of Nevada
    • New Jersey
      • Neptune City, New Jersey, Förenta staterna, 07753
        • Jersey Shore Medical Center
    • New Mexico
      • Albuquerque, New Mexico, Förenta staterna, 87106
        • University of New Mexico Cancer Center
      • Las Cruces, New Mexico, Förenta staterna, 88011
        • Memorial Medical Center-Las Cruces
      • Rio Rancho, New Mexico, Förenta staterna, 87124
        • Presbyterian Rust Medical Center/Jorgensen Cancer Center
    • New York
      • Bay Shore, New York, Förenta staterna, 11706
        • Northwell Health Imbert Cancer Center
      • Brightwaters, New York, Förenta staterna, 11718
        • Island Gynecologic Oncology
      • Buffalo, New York, Förenta staterna, 14263
        • Roswell Park Cancer Institute
      • Lake Success, New York, Förenta staterna, 11042
        • Northwell Health/Center for Advanced Medicine
      • Syracuse, New York, Förenta staterna, 13210
        • State University of New York Upstate Medical University
      • White Plains, New York, Förenta staterna, 10601
        • Dickstein Cancer Treatment Center
    • North Carolina
      • Clinton, North Carolina, Förenta staterna, 28328
        • Southeastern Medical Oncology Center-Clinton
      • Goldsboro, North Carolina, Förenta staterna, 27534
        • Southeastern Medical Oncology Center-Goldsboro
      • Jacksonville, North Carolina, Förenta staterna, 28546
        • Southeastern Medical Oncology Center-Jacksonville
    • Ohio
      • Akron, Ohio, Förenta staterna, 44304
        • Summa Health System - Akron Campus
      • Alliance, Ohio, Förenta staterna, 44601
        • Aultman Alliance Community Hospital
      • Beachwood, Ohio, Förenta staterna, 44122
        • UHHS-Chagrin Highlands Medical Center
      • Belpre, Ohio, Förenta staterna, 45714
        • Strecker Cancer Center-Belpre
      • Canton, Ohio, Förenta staterna, 44710
        • Aultman Health Foundation
      • Centerville, Ohio, Förenta staterna, 45459
        • Miami Valley Hospital South
      • Chardon, Ohio, Förenta staterna, 44024
        • Geauga Hospital
      • Chillicothe, Ohio, Förenta staterna, 45601
        • Adena Regional Medical Center
      • Cincinnati, Ohio, Förenta staterna, 45220
        • Good Samaritan Hospital - Cincinnati
      • Cincinnati, Ohio, Förenta staterna, 45242
        • Bethesda North Hospital
      • Cincinnati, Ohio, Förenta staterna, 45247
        • TriHealth Cancer Institute-Westside
      • Cincinnati, Ohio, Förenta staterna, 45255
        • TriHealth Cancer Institute-Anderson
      • Cleveland, Ohio, Förenta staterna, 44106
        • Case Western Reserve University
      • Cleveland, Ohio, Förenta staterna, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Förenta staterna, 44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus, Ohio, Förenta staterna, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Förenta staterna, 43210
        • Ohio State University Comprehensive Cancer Center
      • Columbus, Ohio, Förenta staterna, 43219
        • The Mark H Zangmeister Center
      • Columbus, Ohio, Förenta staterna, 43214
        • Columbus Oncology and Hematology Associates Inc
      • Columbus, Ohio, Förenta staterna, 43228
        • Doctors Hospital
      • Columbus, Ohio, Förenta staterna, 43213
        • Mount Carmel East Hospital
      • Columbus, Ohio, Förenta staterna, 43215
        • Grant Medical Center
      • Columbus, Ohio, Förenta staterna, 43222
        • Mount Carmel Health Center West
      • Dayton, Ohio, Förenta staterna, 45409
        • Miami Valley Hospital
      • Delaware, Ohio, Förenta staterna, 43015
        • Delaware Health Center-Grady Cancer Center
      • Delaware, Ohio, Förenta staterna, 43015
        • Grady Memorial Hospital
      • Dublin, Ohio, Förenta staterna, 43016
        • Dublin Methodist Hospital
      • Gahanna, Ohio, Förenta staterna, 43230
        • Central Ohio Breast and Endocrine Surgery
      • Grove City, Ohio, Förenta staterna, 43123
        • Mount Carmel Grove City Hospital
      • Lancaster, Ohio, Förenta staterna, 43130
        • Fairfield Medical Center
      • Lima, Ohio, Förenta staterna, 45801
        • Saint Rita's Medical Center
      • Mansfield, Ohio, Förenta staterna, 44903
        • OhioHealth Mansfield Hospital
      • Marietta, Ohio, Förenta staterna, 45750
        • Marietta Memorial Hospital
      • Marion, Ohio, Förenta staterna, 43302
        • OhioHealth Marion General Hospital
      • Mayfield Heights, Ohio, Förenta staterna, 44124
        • Hillcrest Hospital Cancer Center
      • Mentor, Ohio, Förenta staterna, 44060
        • UH Seidman Cancer Center at Lake Health Mentor Campus
      • Mount Vernon, Ohio, Förenta staterna, 43050
        • Knox Community Hospital
      • Newark, Ohio, Förenta staterna, 43055
        • Licking Memorial Hospital
      • Newark, Ohio, Förenta staterna, 43055
        • Newark Radiation Oncology
      • Perrysburg, Ohio, Förenta staterna, 43551
        • Mercy Health - Perrysburg Hospital
      • Portsmouth, Ohio, Förenta staterna, 45662
        • Southern Ohio Medical Center
      • Toledo, Ohio, Förenta staterna, 43623
        • Mercy Health - Saint Anne Hospital
      • Toledo, Ohio, Förenta staterna, 43608
        • Mercy Health - Saint Vincent Hospital
      • Wadsworth, Ohio, Förenta staterna, 44281
        • University Hospitals Sharon Health Center
      • Westerville, Ohio, Förenta staterna, 43081
        • Saint Ann's Hospital
      • Westlake, Ohio, Förenta staterna, 44145
        • UH Seidman Cancer Center at Saint John Medical Center
      • Zanesville, Ohio, Förenta staterna, 43701
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Lawton, Oklahoma, Förenta staterna, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, Förenta staterna, 73104
        • University of Oklahoma Health Sciences Center
      • Oklahoma City, Oklahoma, Förenta staterna, 73120
        • Mercy Hospital Oklahoma City
      • Tulsa, Oklahoma, Förenta staterna, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Baker City, Oregon, Förenta staterna, 97814
        • Saint Alphonsus Cancer Care Center-Baker City
      • Bend, Oregon, Förenta staterna, 97701
        • Saint Charles Health System
      • Clackamas, Oregon, Förenta staterna, 97015
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, Förenta staterna, 97015
        • Providence Cancer Institute Clackamas Clinic
      • Coos Bay, Oregon, Förenta staterna, 97420
        • Bay Area Hospital
      • Newberg, Oregon, Förenta staterna, 97132
        • Providence Newberg Medical Center
      • Ontario, Oregon, Förenta staterna, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
      • Portland, Oregon, Förenta staterna, 97210
        • Legacy Good Samaritan Hospital and Medical Center
      • Portland, Oregon, Förenta staterna, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Förenta staterna, 97225
        • Providence Saint Vincent Medical Center
      • Redmond, Oregon, Förenta staterna, 97756
        • Saint Charles Health System-Redmond
      • Tualatin, Oregon, Förenta staterna, 97062
        • Legacy Meridian Park Hospital
    • Pennsylvania
      • Butler, Pennsylvania, Förenta staterna, 16001
        • UPMC Hillman Cancer Center at Butler Health System
      • Erie, Pennsylvania, Förenta staterna, 16505
        • UPMC Hillman Cancer Center Erie
      • Paoli, Pennsylvania, Förenta staterna, 19301
        • Paoli Memorial Hospital
      • Philadelphia, Pennsylvania, Förenta staterna, 19107
        • Thomas Jefferson University Hospital
      • Philadelphia, Pennsylvania, Förenta staterna, 19114
        • Jefferson Torresdale Hospital
      • Pittsburgh, Pennsylvania, Förenta staterna, 15224
        • West Penn Hospital
      • Pittsburgh, Pennsylvania, Förenta staterna, 15232
        • UPMC Hillman Cancer Center
      • Pittsburgh, Pennsylvania, Förenta staterna, 15213
        • UPMC-Magee Womens Hospital
      • Pittsburgh, Pennsylvania, Förenta staterna, 15237
        • UPMC-Passavant Hospital
      • Willow Grove, Pennsylvania, Förenta staterna, 19090
        • Asplundh Cancer Pavilion
      • Wynnewood, Pennsylvania, Förenta staterna, 19096
        • Lankenau Medical Center
    • Rhode Island
      • Providence, Rhode Island, Förenta staterna, 02905
        • Women and Infants Hospital
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29425
        • Medical University of South Carolina
      • Greenville, South Carolina, Förenta staterna, 29607
        • Saint Francis Cancer Center
      • Greenville, South Carolina, Förenta staterna, 29601
        • Saint Francis Hospital
    • South Dakota
      • Rapid City, South Dakota, Förenta staterna, 57701
        • Rapid City Regional Hospital
    • Tennessee
      • Bristol, Tennessee, Förenta staterna, 37620
        • Bristol Regional Medical Center
      • Kingsport, Tennessee, Förenta staterna, 37660
        • Ballad Health Cancer Care - Kingsport
      • Kingsport, Tennessee, Förenta staterna, 37660
        • Wellmont Holston Valley Hospital and Medical Center
      • Knoxville, Tennessee, Förenta staterna, 37916
        • Covenant Health Cancer Centers
      • Knoxville, Tennessee, Förenta staterna, 37932
        • Covenant Health Cancer Centers - West
      • Nashville, Tennessee, Förenta staterna, 37232
        • Vanderbilt University/Ingram Cancer Center
      • Nashville, Tennessee, Förenta staterna, 37204
        • Vanderbilt Breast Center at One Hundred Oaks
    • Texas
      • Bryan, Texas, Förenta staterna, 77802
        • Saint Joseph Regional Cancer Center
      • Dallas, Texas, Förenta staterna, 75235
        • Parkland Memorial Hospital
      • Dallas, Texas, Förenta staterna, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Houston, Texas, Förenta staterna, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Förenta staterna, 77070
        • Methodist Willowbrook Hospital
      • Houston, Texas, Förenta staterna, 77094
        • Houston Methodist West Hospital
      • Sugar Land, Texas, Förenta staterna, 77479
        • Houston Methodist Sugar Land Hospital
      • The Woodlands, Texas, Förenta staterna, 77385
        • Houston Methodist The Woodlands Hospital
    • Virginia
      • Bristol, Virginia, Förenta staterna, 24201
        • Ballad Health Cancer Care - Bristol
      • Norton, Virginia, Förenta staterna, 24273
        • Ballad Health Cancer Care - Norton
    • Washington
      • Aberdeen, Washington, Förenta staterna, 98520
        • Providence Regional Cancer System-Aberdeen
      • Bellingham, Washington, Förenta staterna, 98225
        • PeaceHealth Saint Joseph Medical Center
      • Burien, Washington, Förenta staterna, 98166
        • Saint Anne Hospital
      • Centralia, Washington, Förenta staterna, 98531
        • Providence Regional Cancer System-Centralia
      • Edmonds, Washington, Förenta staterna, 98026
        • Swedish Cancer Institute-Edmonds
      • Enumclaw, Washington, Förenta staterna, 98022
        • Saint Elizabeth Hospital
      • Everett, Washington, Förenta staterna, 98201
        • Providence Regional Cancer Partnership
      • Federal Way, Washington, Förenta staterna, 98003
        • Saint Francis Hospital
      • Issaquah, Washington, Förenta staterna, 98029
        • Swedish Cancer Institute-Issaquah
      • Kennewick, Washington, Förenta staterna, 99336
        • Kadlec Clinic Hematology and Oncology
      • Lacey, Washington, Förenta staterna, 98503
        • Providence Regional Cancer System-Lacey
      • Lakewood, Washington, Förenta staterna, 98499
        • Saint Clare Hospital
      • Longview, Washington, Förenta staterna, 98632
        • PeaceHealth Saint John Medical Center
      • Port Townsend, Washington, Förenta staterna, 98368
        • Jefferson Healthcare
      • Seattle, Washington, Förenta staterna, 98107
        • Swedish Medical Center-Ballard Campus
      • Seattle, Washington, Förenta staterna, 98122
        • Swedish Medical Center-First Hill
      • Seattle, Washington, Förenta staterna, 98104
        • Pacific Gynecology Specialists
      • Seattle, Washington, Förenta staterna, 98122-5711
        • Swedish Medical Center-Cherry Hill
      • Sedro-Woolley, Washington, Förenta staterna, 98284
        • PeaceHealth United General Medical Center
      • Shelton, Washington, Förenta staterna, 98584
        • Providence Regional Cancer System-Shelton
      • Silverdale, Washington, Förenta staterna, 98383
        • Saint Joseph Medical Center Hematology and Oncology - Silverdale
      • Tacoma, Washington, Förenta staterna, 98405
        • Franciscan Research Center-Northwest Medical Plaza
      • Vancouver, Washington, Förenta staterna, 98686
        • Legacy Salmon Creek Hospital
      • Vancouver, Washington, Förenta staterna, 98664
        • PeaceHealth Southwest Medical Center
      • Walla Walla, Washington, Förenta staterna, 99362
        • Providence Saint Mary Regional Cancer Center
      • Yelm, Washington, Förenta staterna, 98597
        • Providence Regional Cancer System-Yelm
    • West Virginia
      • Charleston, West Virginia, Förenta staterna, 25304
        • Vandalia Health/CAMC Institute for Academic Medicine
    • Wisconsin
      • Green Bay, Wisconsin, Förenta staterna, 54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Green Bay, Wisconsin, Förenta staterna, 54303
        • Saint Vincent Hospital Cancer Center at Saint Mary's
      • La Crosse, Wisconsin, Förenta staterna, 54601
        • Gundersen Lutheran Medical Center
      • Milwaukee, Wisconsin, Förenta staterna, 53226
        • Medical College of Wisconsin
      • Mukwonago, Wisconsin, Förenta staterna, 53149
        • ProHealth D N Greenwald Center
      • New Richmond, Wisconsin, Förenta staterna, 54017
        • Cancer Center of Western Wisconsin
      • Oconomowoc, Wisconsin, Förenta staterna, 53066
        • ProHealth Oconomowoc Memorial Hospital
      • Oconto Falls, Wisconsin, Förenta staterna, 54154
        • Saint Vincent Hospital Cancer Center at Oconto Falls
      • Sturgeon Bay, Wisconsin, Förenta staterna, 54235-1495
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
      • Waukesha, Wisconsin, Förenta staterna, 53188
        • UW Cancer Center at ProHealth Care
      • Waukesha, Wisconsin, Förenta staterna, 53188
        • ProHealth Waukesha Memorial Hospital
    • Wyoming
      • Cody, Wyoming, Förenta staterna, 82414
        • Billings Clinic-Cody
      • Sheridan, Wyoming, Förenta staterna, 82801
        • Welch Cancer Center
  • Puerto Rico
      • Bayamón, Puerto Rico, 00959-5060
        • Cancer Center-Metro Medical Center Bayamon
      • Caguas, Puerto Rico, 00726
        • HIMA San Pablo Oncologic Hospital
      • Manati, Puerto Rico, 00674
        • Doctors Cancer Center
      • Ponce, Puerto Rico, 00716
        • Instituto Oncologia Moderna Ponce
      • San Juan, Puerto Rico, 00917
        • San Juan Community Oncology Group
      • San Juan, Puerto Rico, 00927
        • Centro Comprensivo de Cancer de UPR
      • San Juan, Puerto Rico, 00936
        • San Juan City Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Women with recurrent/persistent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers; platinum-resistant disease is defined as progression within < 6 months from completion of platinum based therapy. The date should be calculated from the last administered dose of platinum therapy

  • Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of high grade serous, grade 3 endometrioid or clear cell carcinoma based on local histopathological findings. Patients with low grade serous, grade 1 or 2 endometrioid, mixed epithelial, undifferentiated carcinoma, or mucinous carcinoma histologies are also eligible, provided that the patient has a known deleterious BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory. Histologic confirmation of the original primary tumor is required via the pathology report (upload of report required). Confirmation of BRCA1 and BRCA2 germline and/or somatic mutation status and hormone receptor (HR) status is required for all entered patients (if available) via testing report (upload of report[s] required)

  • Evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a CA125 >= 2 x upper limit of normal [ULN])

  • Prior therapy:

    • At least two prior treatment regimens (including primary therapy) but up to 5 lines of systemic anticancer therapy. Hormonal therapy (such as tamoxifen, aromatase inhibitors) will not count as a previous treatment regimen.
    • Prior use of bevacizumab in the upfront or recurrent setting is required.
    • Prior use of PARP inhibitor is allowed.
    • Prior use of immune checkpoint blockade (e.g., a PD-L1/PD-1inhibitor or a CTLA-4 inhibitor) is allowed

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

  • Absolute neutrophil count (ANC) >= 1,500/mcL

  • Hemoglobin >= 10 g/dL

  • Platelets >= 100,000/mcL

  • Creatinine clearance (CrCL) or estimated glomerular filtration rate (eGFR) of > 50 mL/min estimated using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR)

  • Urine protein: creatinine ratio (UPC) of =< 1

  • Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN

  • Age >= 18 years

  • Body weight > 30 kg

  • Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on a maximum of three antihypertensive medications. Patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to study registration. It is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on protocol. Patients must be willing and able to check and record daily blood pressure readings. BP cuffs will be provided to patients randomized to the cediranib-containing arms

  • Adequately controlled thyroid dysfunction with no symptoms of thyroid dysfunction and normal thyroid stimulating hormone (TSH). If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal free T4 level is required

  • Able to swallow and retain oral medications and no gastrointestinal (GI) illnesses that would preclude absorption of olaparib and cediranib as judged by treating physician

  • Toxicities of prior therapy (excepting alopecia and vitiligo), should be resolved to less than or equal to grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0

  • Women of childbearing potential (WOCBP) must agree to use two forms of birth control (hormonal or barrier method of birth control; abstinence). Note: Definition of women of no longer having childbearing potential: Postmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within 7 days prior to start of study treatment. Postmenopausal is defined as: Age >= 60 years, or age < 60 with any one or more of the conditions below:

    • Amenorrhoeic for >= 1 year in the absence of chemotherapy and/or hormonal treatments,
    • Luteinizing hormone and/or follicle stimulating hormone and/or estradiol levels in the post-menopausal range,
    • Radiation-induced oophorectomy with last menses > 1 year ago,
    • Chemotherapy-induced menopause with > 1 year interval since last menses,
    • Surgical sterilization (bilateral oophorectomy or hysterectomy)

  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and authorization permitting release of personal health information

Exclusion Criteria:

  • Primary platinum-refractory disease defined as progression during first-line platinum-based chemotherapy

  • Rising CA-125 only without RECIST 1.1 evaluable disease

  • Prior therapy:

    • Patients who have had chemotherapy, investigational drugs or radiotherapy within 3 weeks prior to study registration or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.

    • Patients may not have had hormonal therapy within 2 weeks of study registration. Patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions.

    • Prior use of concurrent olaparib and cediranib combination.

    • Patients who have experienced immune-mediated adverse events requiring dose modification or discontinuation.

    • For patients who have received prior PARP inhibitor:

      • Patients who have required dose modification or dose reduction of olaparib will not be eligible, as they will not be able to start this study at full dose.
      • Patients who have required dose reduction of non-olaparib PARP inhibitors for hematologic adverse events will not be eligible (Note: niraparib that is initiated at 200mg daily per weight and platelet guidelines is not considered a dose reduction).
      • Patients who required dose-reduction of non-olaparib PARP inhibitors for non-hematologic adverse events may be eligible after discussion with the Study Chair if the treating investigator feels that they could appropriately receive olaparib at full dose.

  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 3 months prior to study registration

  • Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months of study registration except temporary (< 24 hr) improved with medical management, within last 3 months

  • Any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1

  • Dependency on IV hydration or total parenteral nutrition (TPN)

  • Pregnant women. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with these drugs, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events. Patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study registration

  • Patients who have the following clinical conditions are considered to be at increased risk for cardiac toxicities. Patients with any cardiac history of the following conditions:

    • History of myocardial infarction or myocarditis within six months of study registration
    • Unstable angina
    • Resting electrocardiogram (ECG) with clinically significant abnormal findings.
    • New York Heart Association functional classification of III or IV

  • If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines. Patients with the following risk factors should have a baseline cardiac function assessment:

    • Prior treatment with anthracyclines
    • Prior treatment with trastuzumab or T-DM1
    • Prior central thoracic radiation therapy (RT), including RT to the heart
    • History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)
    • Prior history of impaired cardiac function

  • History of stroke or transient ischemic attack within six months of study registration

  • Clinically significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)

  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatment. Patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable

  • Evidence of coagulopathy or bleeding diathesis. Therapeutic anticoagulation for prior thromboembolic events, including warfarin, is permitted. Patients receiving warfarin are recommended to have careful monitoring of international normalized ratio (INR)

  • Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated. No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)

  • Human immunodeficiency virus (HIV) positive patients due to potential drug and drug interactions

  • Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments

  • Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment

  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring adverse events or compromise the ability of the patient to given written informed consent

  • Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4. Dihydropyridine calcium-channel blockers are permitted for management of hypertension

  • Current or prior use of immunosuppressive medication within 14 days of study registration. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab, olaparib, or cediranib

  • Patients with active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment

  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis [TB] testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen (HBsAg) result), or hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for hepatitis C virus (HCV) ribonucleic acid (RNA)

  • Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Arm I (paclitaxel, doxorubicin, topotecan hydrochloride))

Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Läkemedel: Paclitaxel

Given IV

Andra namn:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat
Procedur: Computed Tomography

Undergo CT

Andra namn:
  • CT
  • KATT
  • Datortomografi
  • Beräknad axiell tomografi
  • Datoriserad axialtomografi
  • tomografi
  • Datoriserad axiell tomografi (förfarande)
  • Datortomografi (CT) skanning
  • Diagnostisk kattskanning
  • Diagnostisk kattskanningstjänsttyp
Procedur: Magnetic Resonance Imaging

Undergo MRI

Andra namn:
  • MRI
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medicinsk bildbehandling, magnetisk resonans / kärnmagnetisk resonans
  • HERR
  • MR-avbildning
  • MRI-skanning
  • NMR-avbildning
  • NMRI
  • Kärnmagnetisk resonanstomografi
  • Magnetisk resonanstomografi (MRT)
  • sMRI
  • Magnetisk resonanstomografi (förfarande)
  • Strukturell MRI
Procedur: Echocardiography Test

Undergo ECHO

Andra namn:
  • Ekokardiografi
  • EC
Procedur: Multigated Acquisition Scan

Undergo MUGA

Andra namn:
  • Blood Pool Scan
  • Jämviktsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklidventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid Ventrikulogram Scan
  • Gated Heart Pool Scan
  • RNV Scan
Procedur: Biospecimen Collection

Undergo collection of blood

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling
  • Provuppsamling
Läkemedel: Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

Andra namn:
  • ATI-0918
  • Caelyx
  • Doxil
  • Doxilen
  • Doxorubicin HCl-liposomen
  • Duomeisu
  • Evacet
  • LipoDox
  • Liposomal Adriamycin
  • Liposomal-inkapslat doxorubicin
  • Pegylerad doxorubicin HCl liposom
  • S-liposomal doxorubicin
  • Stealth Liposomal Doxorubicin
  • TLC D-99
  • Dox-SL
  • Doxorubicin HCl Liposomal
  • Doxorubicinhydrokloridliposomen
  • Lipodox 50
  • Liposomal doxorubicinhydroklorid
  • Pegylerat liposomalt doxorubicin
  • Liposomal Doxorubicin
Läkemedel: Topotecan Hydrochloride

Given IV

Andra namn:
  • Hycamtin
  • Hycamptamin
  • SKF S-104864-A
  • Topotecan HCl
  • topotekanhydroklorid (oral)
  • Potactasol
  • Evotopin
  • Topotec
  • Nogitecan hydroklorid
  • SKF S 104864 A
  • SKF S104864A
Procedur: Computed Tomography with Contrast

Undergo CT with contrast

Andra namn:
  • Kontrastförbättrad datortomografi
  • KONTRASTFÖRBÄTTAD CT-SCANNING
  • CT-skanning med kontrast
  • CT med kontrast
Experimentell: Arm II (durvalumab, cediranib maleate, olaparib)

Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate PO QD Monday through Friday, and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Procedur: Computed Tomography

Undergo CT

Andra namn:
  • CT
  • KATT
  • Datortomografi
  • Beräknad axiell tomografi
  • Datoriserad axialtomografi
  • tomografi
  • Datoriserad axiell tomografi (förfarande)
  • Datortomografi (CT) skanning
  • Diagnostisk kattskanning
  • Diagnostisk kattskanningstjänsttyp
Procedur: Magnetic Resonance Imaging

Undergo MRI

Andra namn:
  • MRI
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medicinsk bildbehandling, magnetisk resonans / kärnmagnetisk resonans
  • HERR
  • MR-avbildning
  • MRI-skanning
  • NMR-avbildning
  • NMRI
  • Kärnmagnetisk resonanstomografi
  • Magnetisk resonanstomografi (MRT)
  • sMRI
  • Magnetisk resonanstomografi (förfarande)
  • Strukturell MRI
Procedur: Echocardiography Test

Undergo ECHO

Andra namn:
  • Ekokardiografi
  • EC
Procedur: Multigated Acquisition Scan

Undergo MUGA

Andra namn:
  • Blood Pool Scan
  • Jämviktsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklidventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid Ventrikulogram Scan
  • Gated Heart Pool Scan
  • RNV Scan
Procedur: Biospecimen Collection

Undergo collection of blood

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling
  • Provuppsamling
Läkemedel: Cediranib Maleate

Given PO

Andra namn:
  • AZD2171
  • AZD2171 maleat
  • Recentin
Läkemedel: Olaparib

Given PO

Andra namn:
  • Lynparza
  • AZD 2281
  • AZD-2281
  • AZD2281
  • KU-0059436
  • PARP-hämmare AZD2281
  • KU0059436
  • Olanib
  • Olaparix
  • KU 0059436
Procedur: Computed Tomography with Contrast

Undergo CT with contrast

Andra namn:
  • Kontrastförbättrad datortomografi
  • KONTRASTFÖRBÄTTAD CT-SCANNING
  • CT-skanning med kontrast
  • CT med kontrast
Biologisk: Durvalumab

Given IV

Andra namn:
  • Imfinzi
  • Immunoglobulin G1, Anti-(Humant Protein B7-H1) (Human Monoklonal MEDI4736 Heavy Chain), Disulfid med Human Monoklonal MEDI4736 Kappa-kedja, Dimer
  • MEDI-4736
  • MEDI4736
  • MEDI 4736
Experimentell: Arm III (durvalumab, cediranib maleate)

Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Procedur: Computed Tomography

Undergo CT

Andra namn:
  • CT
  • KATT
  • Datortomografi
  • Beräknad axiell tomografi
  • Datoriserad axialtomografi
  • tomografi
  • Datoriserad axiell tomografi (förfarande)
  • Datortomografi (CT) skanning
  • Diagnostisk kattskanning
  • Diagnostisk kattskanningstjänsttyp
Procedur: Magnetic Resonance Imaging

Undergo MRI

Andra namn:
  • MRI
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medicinsk bildbehandling, magnetisk resonans / kärnmagnetisk resonans
  • HERR
  • MR-avbildning
  • MRI-skanning
  • NMR-avbildning
  • NMRI
  • Kärnmagnetisk resonanstomografi
  • Magnetisk resonanstomografi (MRT)
  • sMRI
  • Magnetisk resonanstomografi (förfarande)
  • Strukturell MRI
Procedur: Echocardiography Test

Undergo ECHO

Andra namn:
  • Ekokardiografi
  • EC
Procedur: Multigated Acquisition Scan

Undergo MUGA

Andra namn:
  • Blood Pool Scan
  • Jämviktsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklidventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
  • MUGA Scan
  • Multi-Gated Acquisition Scan
  • Radionuklid Ventrikulogram Scan
  • Gated Heart Pool Scan
  • RNV Scan
Procedur: Biospecimen Collection

Undergo collection of blood

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling
  • Provuppsamling
Läkemedel: Cediranib Maleate

Given PO

Andra namn:
  • AZD2171
  • AZD2171 maleat
  • Recentin
Procedur: Computed Tomography with Contrast

Undergo CT with contrast

Andra namn:
  • Kontrastförbättrad datortomografi
  • KONTRASTFÖRBÄTTAD CT-SCANNING
  • CT-skanning med kontrast
  • CT med kontrast
Biologisk: Durvalumab

Given IV

Andra namn:
  • Imfinzi
  • Immunoglobulin G1, Anti-(Humant Protein B7-H1) (Human Monoklonal MEDI4736 Heavy Chain), Disulfid med Human Monoklonal MEDI4736 Kappa-kedja, Dimer
  • MEDI-4736
  • MEDI4736
  • MEDI 4736
Experimentell: Arm IV (cediranib maleate, olaparib)

Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Procedur: Computed Tomography

Undergo CT

Andra namn:
  • CT
  • KATT
  • Datortomografi
  • Beräknad axiell tomografi
  • Datoriserad axialtomografi
  • tomografi
  • Datoriserad axiell tomografi (förfarande)
  • Datortomografi (CT) skanning
  • Diagnostisk kattskanning
  • Diagnostisk kattskanningstjänsttyp
Procedur: Magnetic Resonance Imaging

Undergo MRI

Andra namn:
  • MRI
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medicinsk bildbehandling, magnetisk resonans / kärnmagnetisk resonans
  • HERR
  • MR-avbildning
  • MRI-skanning
  • NMR-avbildning
  • NMRI
  • Kärnmagnetisk resonanstomografi
  • Magnetisk resonanstomografi (MRT)
  • sMRI
  • Magnetisk resonanstomografi (förfarande)
  • Strukturell MRI
Procedur: Echocardiography Test

Undergo ECHO

Andra namn:
  • Ekokardiografi
  • EC
Procedur: Biospecimen Collection

Undergo collection of blood

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling
  • Provuppsamling
Läkemedel: Cediranib Maleate

Given PO

Andra namn:
  • AZD2171
  • AZD2171 maleat
  • Recentin
Läkemedel: Olaparib

Given PO

Andra namn:
  • Lynparza
  • AZD 2281
  • AZD-2281
  • AZD2281
  • KU-0059436
  • PARP-hämmare AZD2281
  • KU0059436
  • Olanib
  • Olaparix
  • KU 0059436
Procedur: Computed Tomography with Contrast

Undergo CT with contrast

Andra namn:
  • Kontrastförbättrad datortomografi
  • KONTRASTFÖRBÄTTAD CT-SCANNING
  • CT-skanning med kontrast
  • CT med kontrast

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression Free Survival
Tidsram: From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months).

The relationship of randomized treatment assignment to progression free survival. The RECIST 1.1 criteria are used for disease progression. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months).

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Objective Response Rate
Tidsram: From the start of the treatment until disease progression/recurrence, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

Determination of response should take into consideration all target and non-target lesions. Here are the definitions of CR, PR, PD and SD: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters (i.e. the nadir) while on study. The CI is the Jeffreys interval.
From the start of the treatment until disease progression/recurrence, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
Duration of Response
Tidsram: Throughout study treatment, up to 10.6 months.

Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. Duration of response was defined as the time from the first documentation of objective tumor response (complete response (CR) or partial response (PR)) to the first documented progressive disease (PD), or to death due to any cause, whichever occurs first.

Per RECIST, Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as an >=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Reporting the number of months from complete or partial response until disease progression, death or censoring, whichever occurs first. In the absence of disease progression or death, censoring time is based on date of last CT scan.
Throughout study treatment, up to 10.6 months.
Overall Survival
Tidsram: Time from study entry to date of death from any cause, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

Overall survival will be presented by Kaplan Meier methods. Overall Survival (OS) is defined as the duration of time from study entry to date of death from any cause. A subject who has not died will be censored on the date that they were last known to be alive.
Time from study entry to date of death from any cause, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
Count of Participants With a Grade 3 (or Higher) Adverse Event
Tidsram: From the start of treatment until disease progression/recurrence or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

The number of patients (in each reporting group) who experienced a grade 3 (or higher) adverse event
From the start of treatment until disease progression/recurrence or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

National Cancer Institute (NCI)

Samarbetspartners

NRG Oncology

Utredare

  • Huvudutredare: Jung-min Lee, NRG Oncology

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 juni 2021

Primärt slutförande (Faktisk)

26 januari 2023

Avslutad studie (Beräknad)

25 juni 2027

Studieregistreringsdatum

Först inskickad

4 februari 2021

Först inskickad som uppfyllde QC-kriterierna

4 februari 2021

Första postat (Faktisk)

5 februari 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

22 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

21 oktober 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • NCI-2021-00615
  • U10CA180868 (U.S.S. NIH-anslag/kontrakt)
  • NCI-2021-00615 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
  • NRG-GY023 (Annan identifierare: CTEP)
  • NRG-GY023 (Annan identifierare: NRG Oncology)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera